Hemostasis Products Market Size By Product (Topical Hemostasis Product {Gelatin, Polysaccharides , Oxidized Regenerated Cellulose, Collagen}), Infusible Hemostasis Products {Platelet Concentrate From Donor Blood, Fresh Frozen Plasma (FFP), Factor VIII, Pr

Hemostasis Products Market Size By Product (Topical Hemostasis Product {Gelatin, Polysaccharides , Oxidized Regenerated Cellulose, Collagen}), Infusible Hemostasis Products {Platelet Concentrate From Donor Blood, Fresh Frozen Plasma (FFP), Factor VIII, Prothrombin}), Advanced Hemostasis Products ({Flowable, Thrombin, Synthetic Sealants, Fibrin}), By Application (Trauma, Surgery, Hemophilia, Myocardial Infarction), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2030

The hemostasis products market is set to experience robust growth through 2030 owing to expanding geriatric population. Additionally, improving global healthcare infrastructure is likely to further bolster industry growth over the forecast timeline.

Notably, industry players have been adopting profitable strategies to broaden their product offerings, thereby enhancing the overall dynamics of the hemostasis products market. For instance, in February 2021, Teleflex Inc., a medical and surgical instruments manufacturer, acquired Z-Medica, a leading manufacturer of hemostatic products. With this acquisition, Teleflex gained Z-Medica’s QuickClot brand of products, the firm’s proprietary technology that expedites the clotting cascade, which helps achieve hemostasis faster.

To cite another instance, in February 2021, EndoClot Plus, Inc., a U.S.-based medical device company, received FDA approval for its EndoClot PHS, an innovative product that enables Gastroenterologists to stop bleeding promptly and effectively. The EndoClot PHS is a single-use device that can be applied directly to the bleeding site. The FDA clearance was a milestone in furthering gastrointestinal patient care and supplemented the firm’s expansion in the GI Endoscopy space.

The hemostasis products market has been bifurcated on the basis of application, product, end-use, and region.

On the basis of application, the market has been bifurcated into surgery, myocardial infarction, trauma, hemophilia, and others. The trauma segment registered a valuation of more than $300 million in 2021 due to escalating number of trauma cases and rising incidences of road accidents across the world, which has driven product demand.

Based on product, the hemostasis products market has been segmented into infusible hemostasis products, advanced hemostasis products, and topical hemostasis products. Among these, the topical hemostasis products sub-segment is expected to register a CAGR of around 5.9% from 2022 to 2030. Growing geriatric population base and increasing prevalence of cardiovascular diseases are primed to stimulate the expansion of the topical hemostasis products sub-segment in the forthcoming years.

In the context of end-use, the market has been divided into ambulatory surgical centers, hospitals, and others. The ambulatory surgical centers sub-segment is speculated to register notable growth at about 4.9% CAGR through the review period. Technological advancements in hemostasis products and mounting government expenditure in the healthcare sector are foreseen to spur segmental growth.

From the regional perspective, the hemostasis products market in the Latin America region is slated to amass substantial gains, recording approximately 4.6% CAGR from 2022 to 2030. A significant rise in medical tourism in the Southern American countries, coupled with new product launches in the region, is poised to augment hemostasis products industry growth in LATAM over the forecast timeframe.